Nargues Weir is a Respiratory physician. OpenAlex indexes 91 publications with 2,325 citations (h-index 23); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3300 Gallows Rd
Advanced Lung Disease Program
Falls Church, VA 22042
Telephone
703-776-2986Registry record last updated 28 May 2010.
Clinical trials
- Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH)
Sponsor: Inova Health Care Services
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
32.1%Endothelin Receptor Antagonist17.6%Opsumit100%Part D<11 patientsLoop diuretic7.3%Furosemide100%Part D<11 patients+ 1 more class in this area
Genitourinary & hormones
25.9%Phosphodiesterase 5 Inhibitor25.9%Tadalafil46%Adcirca30%Alyq24%Part D<11 patientsCancer & immunology
21.8%Purine Antimetabolite16.1%Azathioprine100%Part D<11 patientsKinase inhibitor5.7%Ofev100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on ‘Feels, Functions, Survives’. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency
American Journal of Respiratory and Critical Care Medicine
2024 - Atorvastatin in Severity-Stratified Pulmonary Sarcoidosis: A Phase II Randomized Controlled Trial
American Journal of Respiratory and Critical Care Medicine
2024 - Asthmatic patients with high serum amyloid A have proinflammatory HDL: Implications for augmented systemic and airway inflammation
Journal of Allergy and Clinical Immunology
2023 - Long‐term tolerability of phosphodiesterase‐5 inhibitors in pulmonary hypertension of sickle cell disease
European Journal Of Haematology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”